Nicotinic acid is a lipid-lowering agent widely used to treat hypertriglyceridemia and to elevate low high density lipoprotein levels. However, the underlying mechanisms are poorly understood. In this study, G protein activation by nicotinic acid and derivatives was assessed as stimulation of guanosine 5Ј-(␥-[ 
S]GTP␥S binding in membranes from rat adipocytes and spleen, but not from other tissues. G protein activation in adipocyte membranes in the presence of maximally activating concentrations of the selective A 1 adenosine receptor agonist 2-chloro-N 6 -cyclopentyladenosine and nicotinic acid was almost additive, indicating that G proteins of mostly distinct pools were activated by these agonists. G protein activation by nicotinic acid and related substances in spleen and adipocytes revealed identical pharmacological profiles. [ 3 H]Nicotinic acid specifically detected guanine nucleotide-sensitive binding sites of identical pharmacology in adipocyte and spleen membranes. The site of action of nicotinic acid is distinct from other G protein-coupled receptors. These data indicate that nicotinic acid most probably acts on a specific G protein-coupled receptor.
Hypercholesterolemia is a relevant risk factor with regard to the development of atherosclerotic diseases. Inadequate response to dietary therapy may require the administration of lipid-lowering drugs. One strategy to decrease elevated levels of lipids in blood is the inhibition of lipolysis in adipose tissue. This approach involves regulation of hormone-sensitive lipase, which is the rate-limiting enzyme in lipolysis. Lipolytic agents, e.g., ␤-adrenergic agonists, increase cellular levels of cyclic AMP, which, in turn, activates protein kinase A and leads to phosphorylation and activation of hormonesensitive lipase (Yeaman, 1990) . In contrast, various antilipolytic agents, e.g., adenosine, act by lowering intracellular cyclic AMP levels (Schwabe et al., 1973) .
Nicotinic acid and the metabolically stable derivative 5-methylpyrazine-2-carboxylic acid-4-oxide (acipimox; Fig. 1 ) are commonly used drugs for the treatment of hyperlipidemia (DiPalma and Thayer, 1991) . The benefits of nicotinic acid in the treatment or prevention of atherosclerotic cardiovascular disease have been documented in six major clinical trials (for review, see Guyton, 1998) . Among other hypolipidemic agents, nicotinic acid seems unique because of its potential to increase high density lipoprotein cholesterol to a greater extent than other drugs (Kwiterovich, 1998) . Nicotinic acid and related heterocyclic compounds inhibit lipolysis in adipose tissue. This action of nicotinic acid and analogs involves a decrease in cellular cyclic AMP levels by inhibition of adipocyte adenylyl cyclase (Aktories et al., 1980a) and stimulation of a high-affinity GTPase in fat cell membranes (Aktories et al., 1980b (Aktories et al., , 1982 . The inhibition of adenylyl cyclase requires a functional G protein of the G i /G o family because GTPase activation as well as adenylyl cyclase inhibition are prevented by pertussis toxin (Aktories et al., 1983) . In contrast, augmentation of insulin-stimulated glucose transport by nicotinic acid in rat adipocytes requires a pertussis toxin-sensitive G protein, but is probably independent from cyclic AMP (Kuroda et al., 1987; Honnor et al., 1992) .
The most frequently observed side effect of nicotinic acid is skin flushing, which may be ameliorated by low doses of cyclooxygenase inhibitors. Cyclooxygenase inhibitors do not prevent the lipid-lowering actions of nicotinic acid (Kaijser et al., 1979) , which indicates that these effects are mediated via distinct mechanisms, and cyclooxygenase products are not involved in the inhibition of lipolysis by nicotinic acid.
Although to date it is known that the hypolipidemic effects of nicotinic acid involve adenylyl cyclase inhibition via a pertussis toxin-sensitive G protein, knowledge about the pri-mary site and mechanism of action of nicotinic acid is scarce. In the present study, we have characterized the requirements for G protein activation by nicotinic acid in membranes of rat adipocytes. Structure-activity relationships for G protein activation by nicotinic acid and analogs were investigated. In addition, the site of action of nicotinic acid and related heterocycles was characterized with respect to localization in rat tissues. For the first time, a distinct membraneassociated nicotinic acid binding site of appropriate pharmacology has been identified in direct binding studies. Therefore, it must be concluded that the primary site of action of nicotinic acid is a specific membrane-bound receptor.
Experimental Procedures

Materials. Guanosine 5Ј-(␥-[
35 S]thio)-triphosphate ([ 35 S]GTP␥S; 1250 Ci/mmol) was obtained from NEN Life Science Products (Cologne, Germany). [5, H]Nicotinic acid (50-60 Ci/mmol) was purchased from Biotrend (Cologne, Germany). 2-Chloro-N 6 -cyclopentyladenosine (CCPA) and pyridine-2,3-dicarboxylic acid (quinolinic acid) came from RBI/Sigma (Deisenhofen, Germany). Imidazole-4-acetate was purchased from Tocris (Bristol, England). 6-Methylnicotinic acid, furane-3-carboxylic acid, 2-hydroxynicotinic acid, imidazole-4-carboxylic acid, indole-3-carboxylic acid, 2-methylnicotinic acid, 5-methylpyrazine-2-carboxylic acid, nicotinic acid-1-oxide, piperidine-3-carboxylic acid, pyrazine-2,3-dicarboxylic acid, pyrazine-2-carboxylic acid, 3-pyridine-acetic acid, 3-(3-pyridine)-propionic acid, and quinoline-3-carboxylic acid came from Sigma-Aldrich (Deisenhofen, Germany). Benzoic acid, collagenase (from Clostridium histolyticum, type II), isonicotinic acid (pyridine-4-carboxylic acid), nicotinic acid (pyridine-3-carboxylic acid), nicotinamide, pertussis toxin, NAD, GTP␥S, bovine serum albumin (fraction V), piperazine-2-carboxylic acid, pyridine-3,5-dicarboxylic acid, and quinoline-3-carboxylic acid (quinaldic acid) were purchased from Sigma (Deisenhofen, Germany). Adenosine deaminase, ATP, GDP, guanosine 5-(␤-thio) diphosphate (GDP␤S), dithiothreitol, and 3-[(3-cholamidopropyl) dimethylammonio]propanesulfonate (CHAPS) were purchased from Roche Biochemicals (Mannheim, Germany). Acipimox was a generous gift from Pharmacia-Upjohn (Erlangen, Germany). All other materials were from standard sources and of the highest purity commercially available.
Synthesis. 4-Methylnicotinic acid and 5-methylnicotinic acid were synthesized according to a published procedure (Clarke et al., 1984) . Pyridazine-4-carboxylic acid was prepared as described (Leanza et al., 1953) .
Membrane Preparations. Male Wistar rats (6-8 weeks old, body weight ϳ150 g) were anesthetized with ether and decapitated. Isolated fat cells from epididymal, omental, and renal fat pads were prepared by collagenase digestion according to the method of Rodbell (1964) in 123 mM NaCl, 6 mM KCl, 3 mM CaCl 2 , 1.5 mM KH 2 PO 4 , 1.5 mM MgSO 4 , 32 mM NaHCO 3 , 11 mM glucose, and 1% bovine serum albumin, pH 7.4, at 37°C. Membrane preparations from isolated adipocytes were performed according to McKeel and Jarett (1970) . The membranes were resuspended in 50 mM Tris-HCl buffer, pH 7.4, frozen in liquid nitrogen and stored at Ϫ75°C. Membranes from other rat organs (forebrain, spleen, liver, kidney, testis, heart, lung) were prepared after homogenization of tissues in a 9-fold volume of ice-cold 0.32 M sucrose with a polytron (Kinematika, Luzern, Switzerland) for 20 s (setting 6). All subsequent steps were performed at 0 to 4°C. Homogenates were centrifuged for 10 min at 1000g [3200 rpm in a Beckman (Palo Alto, CA) JA-17 rotor]. The supernatants were collected and centrifuged for 40 min at 100,000g (37,000 rpm in a Beckman Ti-60 rotor). The pellet was resuspended in H 2 O with a polytron, centrifuged for 30 min at 100,000g, and washed twice as described above with 50 mM Tris-HCl, pH 7.4. The membranes were resuspended in the same buffer, frozen in liquid nitrogen, and stored at Ϫ75°C. Protein concentrations were measured according to the method described by Peterson (1977) , using bovine serum albumin as standard.
[ 35 S]GTP␥S Binding. G protein activation by agonists in rat membrane preparations was assessed as stimulation of [ 35 S]GTP␥S binding as described previously (Lorenzen et al., 1993 (Lorenzen et al., , 1996 . Briefly, samples were incubated in a total volume of 100 l containing 50,000 cpm (0.2 nM) [
35 S]GTP␥S, 50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 5 mM MgCl 2 , 1 mM dithiothreitol, 100 mM NaCl, 10 M GDP, 0.5 U/ml adenosine deaminase, and 0.5% bovine serum albumin, if not indicated otherwise. Incubations were performed with 0.5 to 2 g of membrane protein for 90 min at 25°C and were terminated by filtration over GF/B glass fiber filters (Whatman, Maidstone, England) followed by two 4-ml washes with ice-cold buffer (50 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 0.02% CHAPS). Adenosine deaminase was added to all samples to remove endogenous adenosine, which leads to background activation of G proteins in the absence of exogenous agonists (Laitinen and Jokinen, 1998) . ]nicotinic acid to membranes from rat tissues was done with 50 to 100 g of membrane protein per tube in a total volume of 250 l in 50 mM Tris-HCl, pH 7.4, containing 0.02% CHAPS. In the presence of 0.02% CHAPS, nonspecific binding was lower than in its absence, with no effect on specific binding. In some experiments, MgCl 2 was added to a final concentration of 1 mM. Binding experiments were conducted, if not indicated otherwise, in the presence of 20 nM radioligand for 3.5 h at 25°C, according to previous time course experiments. Nonspecific binding was assessed in the presence of 100 M acipimox. In kinetic experiments, dissociation of the radioligand was induced by addition of acipimox (final concentration 100 M). Separation of membrane-bound from unbound radioligand was done by filtration of the samples through nitrocellulose filters and two washing steps, each with 4 ml of 50 mM Tris-HCl (pH 7.4) with 0.02% CHAPS.
ADP-Ribosylation of Membranes with Pertussis Toxin. Pertussis toxin (200 g/ml) was preactivated in the presence of 50 mM dithiothreitol for 1 h at 20°C. ADP-ribosylation was performed for 1 h at 25°C with 20 g of activated toxin/ml, 1 mg of protein/ml of adipocyte, or spleen membranes in 50 mM Tris-HCl pH 7.4, 3 mM NAD, 1 mM ATP, 2 mM GDP, and 25 mM dithiothreitol. Control membranes were subjected to identical treatment, but pertussis toxin was omitted. Lean et al., 1982) . Results were fitted to a one-site model if curve fitting to two sites did not improve the fit significantly (p Ͻ 0.05, f-test). EC 50 , K d , and K i values are given as geometric means with 95% confidence limits from 3 to 10 experiments. All other data are arithmetic means Ϯ S.E. Statistical analysis of differences was performed using the Student's t test. Multiple comparisons were performed after analysis of variance followed by the multiple comparison Student-Newman-Keuls test. Results were considered significantly different when p Ͻ 0.05.
Results
Nicotinic acid stimulates [
35 S]GTP␥S binding in adipocyte membranes, which reflects the GDP-GTP exchange reaction in G protein activation. The levels of maximum stimulation by nicotinic acid were 2-to 3-fold above basal levels in rat adipocyte membranes from epididymal, renal, and abdominal fat ( Fig. 2A ). Sensitivity to nicotinic acid did not differ in adipocyte membranes obtained from the different localizations. EC 50 values of nicotinic acid in G protein activation were 1.05 (0.95-1.16) M for adipocyte membranes from epididymal fat pads, 1.32 (0.63-2.74) M in membranes from abdominal, and 1.61 (0.84 -3.05) M in membranes from renal fat pads. For further experiments, membranes from epididymal fat cells were used.
The influence of nicotinic acid on the G protein activational state was further characterized in comparison to the effects of CCPA, which acts as a selective agonist of the G proteincoupled A 1 adenosine receptor in adipocytes. Stimulation of [ 35 S]GTP␥S binding by nicotinic acid and CCPA showed an absolute requirement for the presence of GDP (Fig. 3) . GDP decreases basal binding of the radioligand to a greater extent than binding in the presence of CCPA or nicotinic acid. The maximum of agonist-induced increases in [
35 S]GTP␥S binding were observed at 1 to 10 M GDP (Fig. 3) . Therefore, further experiments were performed in the presence of 10 M this nucleotide. In the following experiments, we investigated whether nicotinic acid, via an unknown mechanism, and CCPA, via activation of A 1 adenosine receptors, stimulate [
35 S]GTP␥S binding to identical or distinct G protein pools. Concentration-dependent G protein activation by CCPA and nicotinic acid was measured in the absence or presence of a maximally stimulating concentration of the second agonist, and concentration-response curves are shown in Fig The total stimulation by both agonists simultaneously present was 2216 Ϯ 361 cpm/g, which corresponds to 79.7% of the expected stimulation (2780 cpm/g) if both agonists were fully additive. Therefore, we assume that nicotinic acid and CCPA activate G protein pools that are, to the greatest part, not identical. In agreement with this result, we found that the potencies of CCPA and nicotinic acid were identical in the absence or presence of the second agonist, indicating an absence of mutual regulation of both G protein activation pathways.
Structure-activity relationships were investigated for heterocyclic compounds related to nicotinic acid by assessing their potency and maximum stimulatory effects in G protein activation in adipocyte membranes (Table 1) . Nicotinic acid was the most potent agent. The carboxyl group of nicotinic acid is essential for its stimulatory activity, because nicotinamide was virtually inactive in concentrations up to 1 mM. 3-Pyridine-acetic acid (EC 50 16.4 M) and 3-(3-pyridine)-propionic acid (inactive up to 1 mM) were much less potent than nicotinic acid. Substitution of nicotinic acid with methyl groups in positions 5 or 6 greatly diminished potency (EC 50 5-methylnicotinic acid, 30.2 M; 6-methylnicotinic acid, 72.6 M). 2-Methyl-and 4-methyl-nicotinic acid were inactive. Other heterocyclic agents that also proved to stimulate G protein activation were pyridazine Ͼ pyrazine Ͼ furane derivatives. Although oxidation of the pyridine ring nitrogen and a 5-methyl-substituent diminish the potency of nicotinic acid approximately 60-and 20-fold, and pyrazine-2-carboxylic acid is also approximately 20-fold less potent than nico- molpharm.aspetjournals.org tinic acid, acipimox displayed only 7-fold lower potency than nicotinic acid in G protein activation (EC 50 10.3 M). Isonicotinic acid, benzoic acid, indole-3-carboxylic acid, imidazole derivatives (imidazole-4-carboxylic acid, imidazole-4-acetate), quinoline derivatives (quinoline-2-carboxylic acid, quinoline-3-carboxylic acid), and compounds with two carboxyl groups (quinolinic acid, pyridine-3,5-dicarboxylic acid, pyrazine-2,3-dicarboxylic acid, pyridazine-4,5-dicarboxylic acid) did not enhance G protein activation. The nonaromatic analogs piperidine-3-carboxylic acid and piperazine-3-carboxylic acid were also inactive in concentrations up to 1 mM, indicating that an aromatic ring is required for the stimulatory effect.
Because nicotinic acid affects not only adipose tissues, we investigated whether activation of G proteins by this agent was detectable in membranes from other tissues. In addition to its effect in adipocyte membranes, nicotinic acid induced stimulation of [
35 S]GTP␥S binding only in spleen membranes, but not in membranes from forebrain, liver, kidney, testis, heart, or lung (Fig. 5) . Further studies sought to determine whether the stimulatory site in adipocyte and spleen membranes were identical. With the exception of 5-methylpyrazine-2-carboxylic acid, which was ϳ3-fold more potent in G protein activation in spleen membranes than in adipocyte membranes, stimulation of [
35 S]GTP␥S binding in spleen and fat cell membranes displayed identical pharmacological profiles (Table 1) . Therefore, we assume that these two sites are identical.
The site of action of nicotinic acid was further characterized by direct binding studies using (Fig. 2B ). In agreement with the ability of nicotinic acid to activate G proteins only in membranes from fat cells and spleen, [ 3 H]nicotinic acid labeled sites in spleen membranes, but not in membranes prepared from other organs (Fig. 6) (Fig. 8) . The agonist-induced increases in GTP␥S binding were fitted to saturation isotherms (Fig. 8, inset) (Fig. 9) . GTP␥S was more effective than GDP␤S in inhibition of radioligand binding. However, the effects of these guanine nucleotides were rather weak. The omission of CHAPS from the incubations did not increase the effects of GDP␤S and GTP␥S (not shown). The low efficacy of GTP␥S and GDP␤S is not attributable to the lack of Mg 2ϩ ions, since identical results were obtained in the absence (Fig. 9) and presence of 1 mM MgCl 2 (not shown). The possibility that the low efficacy of the guanine nucleotides was attributable to labeling of high-and low-affinity binding sites by [ 3 H]nicotinic acid was addressed in competition experiments with unlabeled nicotinic acid in the absence or presence of 10 and 100 M GTP␥S. All inhibition curves were monophasic. GTP␥S led to a stepwise decrease in the affinity from 35.8 (27.6 -46.4) nM under control conditions to 53.3 (45.6 -62.2) nM in the presence of 10 M and to 64.4 (50.7-81.7) nM in the presence of 100 M this nucleotide (each p Ͻ 0.05 versus control). B max values were significantly reduced to 53.9 Ϯ 4.3% in the presence of 10 M and to 34.1 Ϯ 2.2% in the presence of 100 M GTP␥S. Almost identical results were obtained in the presence of 1 mM MgCl 2 (not shown).
Since the yield of membranes from rat spleen (ϳ10 mg/ animal) is considerably higher than that from epididymal adipocytes (ϳ0.5 mg/animal), the binding site labeled with Likewise, when the assay was performed in the presence of 100 mM sodium chloride and 1 M GDP instead of 10 M, an EC 50 value of 237 (122-460) nM was determined.
It has been reported previously that GTPase activation and adenylyl cyclase inhibition by nicotinic acid in adipocyte membranes are pertussis toxin-sensitive (Aktories et al., 1983) . In agreement with these findings, we found that pertussis toxin pretreatment of rat adipocyte membranes reduced stimulation of [
35 S]GTP␥S binding to 24.5 Ϯ 7.6% of control membranes (four experiments). In contrast, [
3 H]nicotinic acid binding to spleen membranes was reduced only to 84.3 Ϯ 5.6% by pertussis toxin.
Discussion
Nicotinic acid and related heterocyclic agents activate pertussis toxin-sensitive GTPase and inhibit adenylyl cyclase in a hormone-like manner (Aktories et al., 1980a (Aktories et al., ,b, 1982 (Aktories et al., , 1983 . A specific receptor has been proposed (Aktories et al., 1980a) , but no direct evidence for its existence has been presented so far. In the present study, we have used a different approach to characterize the effects of nicotinic acid on G proteins. 1980b), indicating that the three different approaches characterize the same transduction pathway. In agreement with a previous study on adenylyl cyclase inhibition (Aktories et al., 1980c) , nicotinamide was inactive in G protein activation determined as stimulation of [
35 S]GTP␥S binding (Table 1) . We investigated whether nicotinic acid might activate known G protein-coupled receptors. However, the site through which nicotinic acid induces G protein activation is distinct from other G i /G o -coupled receptors, which have been detected previously in adipocyte or spleen membranes. Binding sites for neuropeptide Y or peptide YY are detectable in adipocyte membranes from human, dog, and mouse fat cells, but not in membranes from rat adipocytes (Castan et al., 1994) . The ␣ 2 -adrenergic agonist 5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine (UK 14,304) did not stimulate [
35 S]GTP␥S binding in adipocyte or spleen membranes (data not shown), in agreement with the finding that UK 14,304 inhibits lipolysis in adipocytes from old rats (at least 12 weeks old and ϳ340 g of weight), but not in younger animals (Gasic and Green, 1995) , as used in the present study (6 -8 weeks, ϳ150 g). Glucagon-like peptide-1 (1-36) amide and glucagon-like peptide-1 (7-36) amide inhibit isoproterenol-stimulated lipolysis and decrease cyclic AMP levels in 3T3-L1 adipocytes through a receptor distinct from the pancreatic receptor for glucagon-like peptide (MontroseRafizadeh et al., 1997). In rat adipocyte membranes, glucagon-like peptide-1 (1-36) amide did not stimulate [ 35 S]GTP␥S binding (not shown), which excludes the possibility that nicotinic acid might act on receptors for glucagonlike peptide-1. Membrane receptors for angiotensin II (subtype 1) have been characterized previously in rat epididymal adipocyte membranes (Crandall et al., 1993) . However, angiotensin II did not mimic the stimulatory effect of nicotinic acid in G protein activation, and the angiotensin receptor antagonist [Sar 1 ,Ile 8 ]angiotensin II did not affect the stimulation by nicotinic acid (data not shown). Somatostatin binding sites have been identified in rat adipocytes (Simón et al., 1988) . All five somatostatin receptor subtypes inhibit adenylyl cyclase via G proteins (Hoyer et al., 1994) , and their mRNAs are also detectable in rat spleen (Bruno et al., 1993) . The analog somatostatin (1-14), which is a potent and nonselective agonist at all somatostatin receptor subtypes (Hoyer et al., 1994) , did not stimulate [
35 S]GTP␥S binding to adipocyte membranes (not shown). Therefore we conclude that the nicotinic acid effect is independent from somatostatin receptors. Nonselective agonists of muscarinic receptors (carbachol) and cannabinoid receptors [R(ϩ)-WIN 55,212-2 mesylate] were also inactive (data not shown).
The actions of nicotinic acid were compared with the effects of CCPA, which is an agonist of the G protein-coupled A 1 adenosine receptor. Like CCPA, the stimulatory effect of nicotinic acid required the presence of micromolar concentrations of GDP (Fig. 3) . A 1 adenosine receptors and the putative nicotinic acid receptor are present in rat epididymal adipocyte membranes in approximately the same densities. When A 1 receptors were labeled with the agonist radioligand [ 3 H]R-N 6 -phenylisopropyladenosine (R-PIA), a binding density of 1890 fmol/mg of membrane protein has been measured (Trost and Schwabe, 1981) . The density of [ 3 H]nicotinic acid binding sites determined in the present study (1518 Ϯ 115 fmol/mg) is in the same range as that for A 1 receptors in fat cell membranes. The A 1 -selective agonist CCPA and nicotinic acid induce a similar magnitude of G protein activation above basal levels (Fig. 8) Although CCPA and nicotinic acid are similarly effective in activation of pertussis toxin-sensitive G proteins in adipocyte membranes, it has been shown in long-term treatments of rat adipocytes with A 1 receptor agonists or nicotinic acid that the effects of these agents are not equal. Prolonged incubation of adipocytes with A 1 adenosine receptor agonists decreases the density of A 1 receptors, leads to a decrease in the content of G protein ␣ i1 -, ␣ i2 -, ␣ i3 -, and ␤-subunits and attenuates the antilipolytic response to A 1 agonist as well as to insulin (Green, 1987; Green et al., 1990 Green et al., , 1997 . In contrast, desensitization with nicotinic acid diminishes the sensitivity of adipocytes to nicotinic acid, but not to insulin, and down-regulation of G proteins is not observed (Green, 1987; Green et al., 1997) . Heterologous desensitization via down-regulation of G i is induced by prolonged incubation of adipocytes in the presence of the A 1 adenosine receptor agonist R-PIA (Green et al., 1992) . Pretreatment with R-PIA diminishes the antilipolytic effects of R-PIA, but also of PGE 1 and, to a smaller degree, that of nicotinic acid. In contrast, nicotinic acid pretreatment, possibly due to the absence of G i down-regulation, exclusively diminishes the responsiveness to nicotinic acid, but not to R-PIA or prostaglandin E 1 , pointing to a fundamental difference in the regulation of G proteins by A 1 receptor agonists and nicotinic acid. In line with these observations in desensitization studies, we have found that activation of G proteins by the A 1 -selective agonist CCPA and nicotinic acid are almost additive, without mutual effects of these agonists on the potency of the second agonist (Fig. 4) . This finding does not necessarily imply that A 1 receptors and the nicotinic acid receptors are coupled to distinct G protein subtypes. G i2 is the most important transducer of hormonal inhibition of adenylate cyclase by R-PIA and nicotinic acid in adipocytes, with G i1 or G i3 capable of the same action, but with lower efficacy (Rudolph et al., 1996) . The G protein pools activated by A 1 adenosine receptors and nicotinic acid may belong to functionally compartmentalized G protein pools and are therefore subject to different modes of regulation. (Fig. 7) , the same tissue membranes in which nicotinic acid-induced G protein activation had been observed (Fig. 5) (Fig. 9) , as expected for agonist binding to the high-affinity state of G protein-coupled receptors. However, the Scatchard plots of [ 3 H]nicotinic acid saturation experiments in spleen membranes were slightly curvilinear, which might indicate that the radioligand could label two sites of different affinities. Although fitting the saturation data to a two-site model did not improve the fit significantly, we have addressed this possibility by inhibition of [ 3 H]nicotinic acid binding by unlabeled nicotinic acid in the absence and presence of 10 and 100 M GTP␥S. In the presence of GTP␥S, lower maximum binding capacities were determined, as expected from inhibition experiments shown in Fig. 9 . GTP␥S also reduced the affinity of nicotinic acid approximately 2-fold. Since the inhibition curves in the absence as well as in the presence of GTP␥S were strictly monophasic, the GTP␥S-induced decrease in affinity cannot be attributed to a shift of nicotinic acid receptors from the high-to the low-affinity state. Alternatively, if the binding affinities of this receptor in the G protein-coupled and uncoupled state are not very different, these results do not exclude the possibility that [ 3 H]nicotinic acid labels both affinity states. To clarify this question, a radioligand antagonist would be required, which is currently not available.
In agreement with a previous report (Aktories et al., 1983) , we have found that G protein activation by nicotinic acid in adipocyte membranes is sensitive to pertussis toxin. However, [ 3 H]nicotinic acid to spleen membranes was inhibited by the toxin only to a minor extent. This may indicate that the majority of G proteins coupled to the nicotinic acid receptor in spleen are distinct from G i /G o . On the other hand, [ 3 H]nicotinic acid may bind to G protein-coupled and uncoupled receptors with similar affinities. The relative insensitivity to pertussis toxin in spleen membranes may be due to the possibility that the majority of receptors are uncoupled. This assumption is in agreement with the low efficacies of guanine nucleotides on [
3 H]nicotinic acid binding. Again, to clearly discriminate between these two possibilities, an antagonist radioligand of the nicotinic acid receptor would be required. To conclude, the results support the concept that the effects of nicotinic acid are transduced via a specific G proteincoupled receptor located in membranes of fat and spleen cells. Because it provides a better signal-to-noise ratio and requires less membrane protein, stimulation of [ 35 S]GTP␥S binding to adipocyte membranes by nicotinic acid and analogs is a more advantageous screening method than GTPase and adenylate cyclase studies. Its site of action was characterized for the first time in direct receptor binding studies. The finding that nicotinic acid receptors are present not only in adipocytes but also in spleen may prove to be relevant in understanding the therapeutic effects of this compound. Characterizing the functional effects of nicotinic acid on specific cell types in spleen will be an important issue in further studies. A more detailed functional exploration of the nicotinic acid receptor will be possible when antagonists become available. An important target will be the elucidation of the amino acid sequence and structural properties of this receptor.
